91 related articles for article (PubMed ID: 6245003)
21. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains.
Laassri M; Lottenbach K; Belshe R; Wolff M; Rennels M; Plotkin S; Chumakov K
J Infect Dis; 2005 Dec; 192(12):2092-8. PubMed ID: 16288372
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.
Haastrup E; Thierry-Carstensen B; Jensen AM; Stellfeld M; Heilmann C
Vaccine; 2004 Feb; 22(8):958-62. PubMed ID: 15161072
[TBL] [Abstract][Full Text] [Related]
23. Viral vaccines and residual cellular DNA.
Horaud F
Biologicals; 1995 Sep; 23(3):225-8. PubMed ID: 8527122
[TBL] [Abstract][Full Text] [Related]
24. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.
Sawyer LA; Wood D; Ferguson M; Crainic R; Beuvery EC; McInnis J; Albrecht P
Biologicals; 1997 Sep; 25(3):299-306. PubMed ID: 9324998
[TBL] [Abstract][Full Text] [Related]
25. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
[TBL] [Abstract][Full Text] [Related]
26. A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine.
Wood DJ; Heath AB; Kersten GF; Hazendonk T; Lantinga M; Beuvery EC
Biologicals; 1997 Mar; 25(1):59-64. PubMed ID: 9167009
[TBL] [Abstract][Full Text] [Related]
27. The monitoring of antigen levels during inactivated poliovirus vaccine production: evaluation of filtration techniques.
Moynihan M; Petersen I
Dev Biol Stand; 1981; 50():243-8. PubMed ID: 6804290
[TBL] [Abstract][Full Text] [Related]
28. Concentration and purification of poliovirus by immune adsorption on immobilized antibodies.
van der Marel P; van Wezel AL; Hazendonk AG; Kooistra A
Dev Biol Stand; 1980; 46():267-73. PubMed ID: 6245002
[TBL] [Abstract][Full Text] [Related]
29. Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd.
Von Seefried A; Chun JH; Grant JA; Letvenuk L; Pearson EW
Rev Infect Dis; 1984; 6 Suppl 2(Suppl 2):S345-9. PubMed ID: 6330837
[TBL] [Abstract][Full Text] [Related]
30. World wide experience with inactivated poliovirus vaccine.
Bonnet MC; Dutta A
Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
[TBL] [Abstract][Full Text] [Related]
31. Cell clones cured of persistent poliovirus infection display selective permissivity to the wild-type poliovirus strain Mahoney and partial resistance to the attenuated Sabin 1 strain and Mahoney mutants.
Calvez V; Pelletier I; Couderc T; Pavio-Guédo N; Blondel B; Colbère-Garapin F
Virology; 1995 Oct; 212(2):309-22. PubMed ID: 7571400
[TBL] [Abstract][Full Text] [Related]
32. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
33. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
34. [Polio disposed of, starting in and thanks to the Netherlands?].
Kapsenberg JG
Ned Tijdschr Geneeskd; 1983 Jul; 127(29):1303-5. PubMed ID: 6888596
[No Abstract] [Full Text] [Related]
35. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
[TBL] [Abstract][Full Text] [Related]
36. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
[TBL] [Abstract][Full Text] [Related]
37. Comparison of sensitivity of VERO cell line versus primary monkey kidney cells in the detection of residual live polio virus during and after inactivation.
Montagnon BJ; Nicolas AJ; Fanget B; Peyron L
Dev Biol Stand; 1981; 47():151-5. PubMed ID: 6262146
[TBL] [Abstract][Full Text] [Related]
38. Immunoglobulin a as a serological marker for the (silent) circulation of poliovirus in an inactivated poliovirus-vaccinated population.
Herremans T; Kimman TG; Conyn-Van Spaendonck MA; Buisman A; de Melker H; Abbink F; Bijkerk P; Koopmans MP
Clin Infect Dis; 2002 Apr; 34(8):1067-75. PubMed ID: 11914995
[TBL] [Abstract][Full Text] [Related]
39. Cell substrate for killed poliovaccine production.
Beale AJ
Dev Biol Stand; 1981; 47():19-23. PubMed ID: 6262147
[TBL] [Abstract][Full Text] [Related]
40. Development of inactivated poliovirus vaccine derived from Sabin strains.
Simizu B; Abe S; Yamamoto H; Tano Y; Ota Y; Miyazawa M; Horie H; Satoh K; Wakabayashi K
Biologicals; 2006 Jun; 34(2):151-4. PubMed ID: 16679028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]